In an adult with acute intracerebral hemorrhage (ICH) and acute ischemic stroke, what are the recommended blood pressure targets and management strategies, including for patients who are candidates for intravenous tissue‑type plasminogen activator (tPA)?

Blood Pressure Targets in Acute Intracerebral Hemorrhage and Acute Ischemic Stroke

Acute Intracerebral Hemorrhage (ICH)

For patients with acute ICH presenting within 6 hours with systolic BP 150–220 mmHg, do NOT lower systolic BP below 140 mmHg—this approach provides no mortality or disability benefit and increases renal complications; instead, target systolic BP 140–179 mmHg. 1

Blood Pressure Management Algorithm for ICH

When SBP is 150–220 mmHg (within 6 hours of onset):

• Target range: 140–179 mmHg systolic 1
• Lowering to <140 mmHg carries a Class III: Harm recommendation from ACC/AHA guidelines 1
• The ATACH-2 trial (the highest-quality randomized trial) definitively showed that intensive lowering to 110–139 mmHg versus standard 140–179 mmHg produced no improvement in death or severe disability but significantly increased acute kidney injury 2, 3

When SBP is >220 mmHg:

• Use continuous intravenous infusion with close BP monitoring to lower SBP 1
• This is a Class IIa (reasonable) recommendation 1
• Markedly elevated BP >220 mmHg is independently associated with greater hematoma expansion, neurological worsening, and death 2

Preferred IV Antihypertensive Agents for ICH

First-line agents:

• Labetalol: 10–20 mg IV bolus (repeatable every 10 minutes) or continuous infusion 2–8 mg/min 2

  • Preferred because easily titratable with minimal cerebral vasodilatory effects 2

• Nicardipine: Start 5 mg/h IV, titrate by 2.5 mg/h every 5–15 minutes, maximum 15 mg/h 2

  • Effective alternative, especially useful with bradycardia or heart failure 2

Agents to AVOID:

• Sodium nitroprusside: Contraindicated due to adverse effects on cerebral autoregulation and intracranial pressure; reserve only for refractory hypertension 2
• Sublingual nifedipine: Contraindicated because it cannot be titrated and causes precipitous BP drops 2
• Glyceryl trinitrate (GTN): Should NOT be used—the RIGHT-2 trial showed harmful effects including worse functional outcomes, larger hematoma expansion, and higher mortality in ICH patients 2

Critical Timing Considerations for ICH

• Rapid BP reduction within 60 minutes of presentation is associated with lower hematoma expansion risk, lower early neurologic deterioration, and improved 90-day functional outcomes 4
• Avoid BP reductions >70 mmHg within one hour—this is associated with poorer functional recovery 2
• A more modest drop of 30–45 mmHg over the first hour is recommended 2
• Monitor BP every 5–15 minutes during IV infusion 2

---

Acute Ischemic Stroke

For Patients RECEIVING IV Thrombolysis (tPA)

Blood pressure MUST be lowered to <185/110 mmHg before initiating tPA and maintained <180/105 mmHg for at least 24 hours afterward—this is a Class I (strongest) recommendation. 1, 5

Pre-tPA BP management:

• Target: <185/110 mmHg (MAP <135 mmHg) 1, 5
• If BP cannot be reduced below 185/110 mmHg despite appropriate therapy, tPA is contraindicated 6
• Lower BP slowly to this target 1

Post-tPA BP management:

• Maintain <180/105 mmHg (MAP <130 mmHg) for at least 24 hours 1, 5
• High BP during the first 24 hours after thrombolysis significantly increases risk of symptomatic intracranial hemorrhage 5, 3

Monitoring schedule after tPA:

• Every 15 minutes for 2 hours 5
• Every 30 minutes for 6 hours 5
• Hourly for 16 hours 5

For Patients NOT Receiving Reperfusion Therapy

Maintain permissive hypertension—do NOT treat BP unless systolic ≥220 mmHg or diastolic ≥120 mmHg during the first 48–72 hours; this is a Class III: No Benefit recommendation. 1, 5

Rationale for permissive hypertension:

• Cerebral autoregulation is impaired in the ischemic penumbra 1, 5
• Systemic perfusion pressure is needed for blood flow and oxygen delivery to potentially salvageable brain tissue 1, 5
• Lowering BP below 220/120 mmHg does not reduce death or dependency and may worsen outcomes by compromising cerebral perfusion 1, 5

When BP reaches ≥220/120 mmHg:

• Consider lowering mean arterial pressure by only 15% during the first 24 hours 1, 5
• This is a Class IIb (uncertain benefit) recommendation 1
• Example: from MAP ~153 mmHg to ~130 mmHg 5

Optimal BP range without reperfusion therapy:

• Observational data show a U-shaped mortality curve with optimal admission BP of 121–200 mmHg systolic and 81–110 mmHg diastolic 5
• A systolic range of approximately 150–180 mmHg is considered optimal for supporting collateral circulation 5

Preferred IV Antihypertensive Agents for Ischemic Stroke

First-line agents:

• Labetalol: 10–20 mg IV bolus over 1–2 minutes, repeat or double every 10 minutes (max cumulative 300 mg), or continuous infusion 2–8 mg/min 5

  • Preferred due to ease of titration and minimal cerebral vasodilatory effects 5

• Nicardipine: Start 5 mg/h IV, titrate by 2.5 mg/h every 15 minutes, maximum 15 mg/h 5

  • Effective alternative, especially with bradycardia or heart failure 5

• Clevidipine: 1–2 mg/h IV, dose doubled every 2–5 minutes, maximum 21 mg/h 5

  • Rapid titratable option 5

Agents to AVOID:

• Sublingual nifedipine: Cannot be titrated and causes unpredictable, precipitous BP drops that may compromise cerebral perfusion 5

After the Acute Phase (48–72 Hours)

Restart antihypertensive therapy in neurologically stable patients with BP ≥140/90 mmHg—this is a Class IIa (reasonable) recommendation. 1, 5

• Target for long-term secondary prevention: <130/80 mmHg 1, 5
• Preferred agents: thiazide diuretics, ACE inhibitors, ARBs, or combination therapy 5
• For patients with previously treated hypertension, restarting therapy carries a Class I (strongest) recommendation to reduce recurrent stroke risk 5

---

Critical Exceptions Requiring Immediate BP Control (Override Permissive Hypertension)

Treat BP immediately regardless of stroke type or timing in these conditions:

• Hypertensive encephalopathy 5
• Acute aortic dissection 5
• Acute myocardial infarction 5
• Acute pulmonary edema 5
• Acute renal failure 5

---

Common Pitfalls to Avoid

In ICH:

• Lowering SBP to <140 mmHg in patients with SBP 150–220 mmHg increases renal complications without neurological benefit 1, 2
• Delayed initiation of continuous IV therapy when SBP >220 mmHg permits ongoing hematoma expansion 2
• Using non-titratable agents (sublingual nifedipine, GTN) can cause uncontrolled hypotension 2

In ischemic stroke:

• Treating elevated BP reflexively in patients not receiving tPA—this may represent a compensatory response to maintain cerebral perfusion 5
• Lowering BP too aggressively can extend infarct size by reducing perfusion to the penumbra 5
• Rapid BP reduction can convert potentially salvageable tissue into irreversibly damaged brain 5
• Failing to recognize and correct hypotension, which is associated with poor outcomes 5
• Automatically restarting home antihypertensives during the first 48–72 hours without considering stroke-specific guidelines 5